Figure 1From: A phase II study of concurrent chemo-radiotherapy with weekly nedaplatin in advanced squamous cell carcinoma of the uterine cervix 3-Year progression-free survival rate. The median follow-up duration was 36 months (range: 23–39). Back to article page